XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Cash flows from operating activities:    
Net income $ 13,920,152 $ 7,294,237
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 3,579,474 3,364,432
Stock-based compensation expense 1,156,929 914,003
Deferred income taxes 2,022,965 (1,012,571)
Provision for doubtful accounts 24,098 135,353
Provision for inventory 165,803 790,379
Gain on sale of assets (442,341)  
Tax benefit from exercise of stock options (764,181) (456,796)
Changes in operating assets and liabilities:    
Accounts receivable 4,667,839 716,874
Inventories (3,430,655) (2,433,367)
Prepaid expenses, other current and long-term assets 531,449 429,718
Long-term deposits and other 25,497 25,496
Accounts payable 124,679 (2,399,999)
Accrued expenses (642,430) (873,153)
Deferred revenue (2,150,000) (2,150,000)
Income taxes payable (1,256,367) 1,398,008
Other long-term liabilities (373,712) (6,318)
Net cash provided by operating activities 17,159,199 5,736,296
Cash flows from investing activities:    
Proceeds from sale of assets 530,865  
Purchase of property and equipment (235,803) (1,292,487)
Net cash provided by (used in) investing activities 295,062 (1,292,487)
Cash flows from financing activities:    
Principal payments on debt (1,200,000) (1,200,000)
Proceeds from exercise of stock options 2,932,649 331,639
Tax benefit from exercise of stock options 764,181 456,796
Net cash provided by (used in) financing activities 2,496,830 (411,565)
Exchange rate impact on cash 36,870 46,390
Increase in cash and cash equivalents 19,987,961 4,078,634
Cash and cash equivalents at beginning of period 44,067,477 35,777,222
Cash and cash equivalents at end of period $ 64,055,438 $ 39,855,856